GENOSCIENCE PHARMA Announces its ISO9001:2015 Certification for its R&D and Clinical Activities in Oncology

Marseille, January 13, 2020 - Genoscience Pharma, a clinical-stage biotechnology company dedicated to discovering and developing anticancer treatment drugs, today announces its ISO9001:2015 certification in research, development and clinical activities in the field of oncology. This certification marks the success of months of preparation and demonstrates the commitment of Genoscience Pharma to improve itself in a sustainable way.

"*The ISO9001:2015 certification is a key demonstration of a fully integrated quality approach which reinforces the efficiency and robustness of the development programs managed by Genoscience Pharma's team*" said Dr Cyrille Drouot, Vice-President Quality & CMC.

About Genoscience Pharma

Genoscience Pharma, a French clinical-stage biotechnology company, is developing a potential new disruptive standard of care against liver cancers thanks to our platform. The new chemical entity (drug candidate) GNS561 is an investigational best-in-class drug, tackling cancer cells through targeting lysosomal compartment (functions), which shows outstanding results during its preclinical development and preliminary first-in-human clinical data. In addition to killing cancer cells, for the first time, our small molecule is potentially capable to kill cancer stem cells, bringing a new hope to overcome cancer resistance. Genoscience Pharma is the first clinical stage company ever with new lysosomotropic agents assessed in a global clinical trial. Following an exploration of liver cancer business potential, the company decided to focus on malignant diseases encountering highly unmet medical needs: primary and secondary liver cancers. We are collaborating with several clinical investigators in Europe and in the US who expressed their interest in GNS561.

Forward-Looking Statements

This press release may involve and contain forward-looking statements by the company about its drug candidate GNS561, including its potential benefits. Such statements are based upon the current beliefs and expectations of Genoscience Pharma's management and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, but are not limited to: additional financing, the company's ability to implement its chosen strategy, dependence upon third parties, other risks and uncertainties inherent in research and development, including the possibility of unfavorable study results, changes in the competitive environment, changes in regulations, clinical or industrial risks and all risks linked to the company's growth. There are no guarantees that future clinical trials will be completed or successful or that any Genoscience Pharma therapeutics will receive regulatory approval for any indication or prove to be commercially successful. While those factors presented here are considered representative, no such list should be considered to be a complete statement of all potential risks and uncertainties. Unlisted factors may present significant additional obstacles to the realization of forward-looking statements. Forward-looking statements included herein are made as of the date hereof; Genoscience Pharma does not undertake any obligation to update such statements to reflect subsequent events or circumstances.